An Empirical Investigation of Code Smell ‘Deception’ and Research Contextualisation through Paul’s Criteria

Code smells represent code decay and as such should be eradicated from a system to prevent future maintenance problems. A range of twenty smells described by Fowler and Beck each require varying numbers and combinations of refactorings in order to be eradicated — but exactly how many are needed when we consider related, nested refactorings is unclear. In this paper, we enumerate these refactorings when categorised according to Mantyla’s smell taxonomy. We then show how, ironically, the ‘smelliest’ of smells (and hence most difficult to eradicate) are actually those best understood by developers. So, code smells are not only unpleasant to have around, but are deceptive in their nature and make-up. The study is thus a warning against attempting to eradicate what are seemingly easily eradicated smells — these are often the smells the developer needs to be most wary of. Finally, we incorporate the answers to six questions suggested by Paul for ‘How to write a paper properly’ to position the paper in a reflective way

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Checking states and transitions of a set of communicating finite state machines

Given a model M, consisting of communicating nite state machines (CFSMs), that represents the required behaviour of an implementation I, it is important totestI against M. This paper considers part of the testing process: checking the transition structure of I against that of M. One possible approach, to checking the transition structure of I, is to generate the product machine from M and then test the global transitions using standard nite state machine test techniques. This approach may, however, su er from a combinatorial explosion. Instead, this paper introduces approaches that may allow local states and transitions of I to be checked without the generation of the product machine. The paper then considers the extension of these approaches to the checking of global states

A multi-criteria decision making framework for Real Time model-based testing

Testing Real-Time Embedded Systems (RTES) is a non-trivial task time adds a new dimension to the complexity of the testing process. In previous research, we introduced a 'priority-based' approach which tested the logical and timing behaviour of an RTES modelled formally as Uppaal timed automata. In this paper, we develop a novel Analytical Hierarchy Process (AHP) decision-making framework for our priority-based testing approach that provides testers with a systematic approach through which they can prioritize the available testing sets that best fulfils their testing requirements

2 ConSUS: a light-weight program conditioner

Program conditioning consists of identifying and removing a set of statementswtat cannot be executedwec a condition of 13 interest holds at some point in a program. It has been applied to problems in maintenance, testing, re-use and re-engineering. 14 All current approaches to program conditioning rely upon both symbolic execution and reasoning about symbolic predicates. 15 The reasoning can be performed by a #heavy duty# theorem prover but this may impose unrealistic performance constraints